poisar

Stocks · News reference

PMGC Holdings’ Northstrive Amends Development And License Agreement With Yuva Biosciences To Launch Three-Phase Program Advancing Four AI-Discovered Compounds And Updating AI Scope, IP, Field Of Use, And Financial Terms

Benzinga Newsdesk

Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup.The

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ELAB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — PMGC Holdings Inc. (ELAB)

    Filed: 2026-09-02 AccNo: 0001213900-26-096784 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    ELAB